Washington is currently home to 1780 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
NCT06130540
Recruiting
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of i.v. Secukinumab infusion in adult patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR).
Gender:
All
Ages:
50 years and above
Trial Updated:
06/07/2024
Locations: Overlake Internal Med Associates Research, Bellevue, Washington
Conditions: Giant Cell Arteritis, Polymyalgia Rheumatica
Register for Updates
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828
Recruiting
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer sur... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Providence Regional Cancer System-Aberdeen, Aberdeen, Washington
Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
NCT05904886
Recruiting
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Swedish Cancer Institute - Edmonds Campus, Edmonds, Washington
Conditions: Carcinoma, Hepatocellular
Register for Updates
Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease
NCT05755711
Recruiting
Post-market, prospective, multi-center, single-arm observational study to generate real-world clinical evidence associated with coronary IVL in a population of female subjects with calcified coronary artery disease.
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Coronary Artery Disease
Register for Updates
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.
NCT05686551
Recruiting
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease.
Gender:
All
Ages:
Between 25 years and 50 years
Trial Updated:
06/07/2024
Locations: Evergreen Health Care Center, Kirkland, Washington
Conditions: Huntington Disease
Register for Updates
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451
Recruiting
The purpose of this trial is: to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment to collect safety data in this population for up to three years after the last dose of study treatment
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/07/2024
Locations: Novartis Investigative Site, Seattle, Washington
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
NCT05673083
Recruiting
The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: • Does All4Cure effect patient activation as assessed by the PAM-13 survey? Participants will be asked to: fill out quarterly PAM-13 surveys through the All4Cure website to assess patient activation. fill out monthly Patient Reported Outcome (PRO) surveys through the All4Cure website. fill out a baseline and exit All4Cure surveys through the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Northwest Medical Specialties PLLC, Tacoma, Washington
Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
Register for Updates
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
NCT05661578
Recruiting
The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combination (IV FDC) in participants with histologically confirmed PD-L1-selected solid tumors whose disease is locally advanced, recurrent, or metastatic and for whom an investigational agent in combination with an anti-PD-L1 antibody is considered an acceptable treatment option.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Medical Oncology Associates, Spokane, Washington
Conditions: PD-L1-selected Solid Tumors
Register for Updates
DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795
Recruiting
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
Gender:
All
Ages:
25 years and below
Trial Updated:
06/07/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Low-grade Glioma
Register for Updates
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
NCT05555615
Recruiting
52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (aged 5 to 17 years). ACP-103-069 is a 6-week, randomized, double-blind, fixed-dose, placebo controlled, parallel group study of pimavanserin in children and adolescents with irritability associated with autism spectrum disorder (ASD).
Gender:
All
Ages:
Between 5 years and 18 years
Trial Updated:
06/07/2024
Locations: Eastside Therapeutic Resource, Inc. dba Core Clinical Research, Everett, Washington
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
NCT05523895
Recruiting
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors to study the efficacy and safety of pimavanserin
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
06/07/2024
Locations: Eastside Therapeutic Resource, Inc. dba Core Clinical Research, Everett, Washington
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
NCT05493709
Recruiting
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
Gender:
All
Ages:
Between 2 years and 9 years
Trial Updated:
06/07/2024
Locations: Multicare Health System, Tacoma, Washington
Conditions: Puberty; Precocious, Central
Register for Updates